Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01030328
Other study ID # PH09001
Secondary ID
Status Terminated
Phase Phase 3
First received November 4, 2009
Last updated April 14, 2014
Start date November 2009
Est. completion date July 2011

Study information

Verified date April 2014
Source Piedmont Healthcare
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This study will examine how an approved drug (TriLipix), when used in combination with a statin (a drug that lowers blood cholesterol levels), affects the makeup of plaque. Patients will be randomly assigned to receive either the study treatment (TriLipix plus Atorvastatin) or the comparison treatment (a placebo). Comparison of the effect on the makeup of plaque will be done by using coronary artery computed tomography angiography (CTA), which all participants will have at enrollment and at the end of the study (18 months after enrollment).


Description:

This study will examine how an approved drug (TriLipix), when used in combination with a statin (a drug that lowers blood cholesterol levels), affects the makeup of plaque. Comparison of the effect on the makeup of plaque will be done by using coronary artery CTA, which all participants will have at enrollment and at the end of the study.

Those who meet the eligibility criteria and sign the informed consent will be enrolled on study. Patients will be instructed on nutritional guidelines and other lifestyle changes for heart-healthy living.

If a patient has had a coronary CTA within the past two (2) months, they will not undergo the procedure at enrollment. If the patient has not had a coronary CTA within the past two (2) months, they will undergo a coronary CTA with contrast. Patients will be randomly assigned to receive either the study treatment (135 mg of TriLipix plus 40 mg of Atorvastatin) or the comparison treatment (a placebo or two pills that contains no active treatment). They will have a 50% chance of receiving the study treatment and a 50% chance of receiving the comparison treatment. This is a double-blind study, which means the patient, the research staff, and the physician will not know which treatment the patient is receiving. However, in case of an emergency, this information is immediately available to the physician.

Follow-up visits will occur at 3, 6, 12, and 18 months. All patients will have a CTA at the end of treatment.


Recruitment information / eligibility

Status Terminated
Enrollment 18
Est. completion date July 2011
Est. primary completion date July 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria:

1. Age 18-85

2. CAC 30-400, within 12 months of screening visit, OR intermediate stenosis on coronary artery CTA or invasive angiography (40-69% visual estimation) without the presence of obstructive (=70% visual estimation) Stenosis within 3 months of screening visit

3. LDL-C = 100 mg/dL and LDL-C =190 mg/dL at screening or baseline visit

4. TG>150 mg/dL and TG/HDL>3.5 at screening or baseline visit

5. 10 Year Framingham risk score of = 10%

6. Ability and willingness to provide consent and Authorization for use of PHI

Exclusion Criteria:

1. Previous coronary revascularization (PCI, CABG)

2. Current lipid lowering therapy (includes statins, fibrates, niacin, omega 3 agents, intestinal cholesterol absorption inhibitors, cholestatic cholesterol absorption agents and other anti-lipemic agents.)

3. Known genetic form of hypercholesterolemia (e.g. familial hypercholesterolemia, etc.)

4. Creatinine 1.5 mg/dL or greater at baseline visit

5. Fasting serum triglycerides 500 mg/dL or greater at screening or baseline visit

6. Inability to perform CTA:

1. Arrhythmia precluding diagnostic CT examination

2. Known moderate or severe allergy to iodine-based contrast agents (mild prior reactions that could be treated as an outpatient or that could be prevented by pre-medication in the past do not constitute exclusion)

7. Uncontrolled hypertension (SBP>180 mmHg or DBP>130 mmHg on stable treatment)

8. Decompensated heart failure (NYHA class IV) at the time of enrollment

9. Known Pregnancy

10. Inability or unwillingness to consent and Authorization for use of PHI

11. Presence of any co-morbidity that makes life expectancy less than 24 months

12. Inability or unwillingness to comply with follow up procedures

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic


Intervention

Drug:
Placebo
2 sugar pills by mouth once a day.
TriLipix
135 mg of TriLipix + 40 mg of Atorvastatin by mouth once a day

Locations

Country Name City State
United States Piedmont Hospital Atlanta Georgia

Sponsors (1)

Lead Sponsor Collaborator
Piedmont Healthcare

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in calcified plaque volume/percent, non-calcified high-density plaque volume/percent, and low-density plaque volume/percent 18, 24, 30, and 36 months after initiation No
Secondary The secondary endpoint of the study will be the change in PAV of the "Study Lesion" from baseline to follow-up. PAV will be expressed as a ratio of the plaque volume/total vessel volume. 24, 30, and 36 months after initiation No
See also
  Status Clinical Trial Phase
Completed NCT02335086 - DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease N/A
Withdrawn NCT02265146 - ORACLE-NIRS: Lipid cORe Plaque Association With CLinical Events: a Near-InfraRed Spectroscopy Study
Completed NCT00811772 - Trial of Drug Eluting Stent Versus Bare Metal Stent to Treat Coronary Artery Stenosis N/A
Recruiting NCT03322332 - Adipokines of Epicardial Adipose Tissue and Atherosclerosis of Coronary Arteries N/A
Completed NCT02305953 - Cytokines and Vascular Inflammation in Psoriasis N/A
Completed NCT01642173 - Assessment of Coronary Plaque Composition Using Optical Coherence Tomography Phase 1
Completed NCT02316782 - Bifurcation Lesion Analysis and STenting / BLAST
Completed NCT00548613 - Combination Stem Cell (MESENDO) Therapy for Utilization and Rescue of Infarcted Myocardium Phase 1
Terminated NCT00243308 - Serp-1 for the Treatment of Acute Coronary Syndrome Phase 2
Recruiting NCT05105750 - A Comparative Study of Indobufen and Aspirin in Patients With Coronary Atherosclerosis Phase 4
Completed NCT01722214 - Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis Phase 4
Suspended NCT00790764 - Phase II Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia(CI) Phase 2
Active, not recruiting NCT01061398 - CT-FIRST: Cardiac Computed Tomography Versus Stress Imaging For Initial Risk STratification N/A
Completed NCT00431717 - Coronary Computed Tomography Angiography and SPECT in Asymptomatic Diabetes N/A
Completed NCT00431977 - Validation Study of Coronary CT Angiography as a Screening Tool in Asymptomatic Diabetes N/A
Recruiting NCT00155350 - Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients Phase 4
Recruiting NCT05708547 - Role of Mitophagy in Myeloid Cells During Coronary Atherosclerosis.
Terminated NCT02440646 - Natural History of Coronary Atherosclerosis in Real-World Stable Chest Pain Patients Underwent Computed Tomography Angiography in Comparison With Invasive Multimodality Imaging
Completed NCT02576704 - Prognostic Value of Myocardial Perfusion Heterogeneity in Normal SPECT Studies N/A
Terminated NCT01268319 - CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow N/A